Direct-To-Final FDAMA Reporting Rule To Be Effective Sept. 24
This article was originally published in The Gray Sheet
FDA is receiving comments until July 27 on a proposed direct-to-final rule implementing the FDA Modernization Act provision that modifies the medical device reporting regulations. The rule becomes final Sept. 24 barring any substantive negative comments.
You may also be interested in...
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.
Nutritional Brands rolls out NB Pure as brand, including logo, packaging design and website, for all its supplements after 25 years. “When you looked at our label for one brand and looked at the label for another brand, there was no symmetry between the two,” says CEO Danna Pratt.
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.